Drug Type Small molecule drug |
Synonyms Taladegib (USAN/INN), ENV 101, ENV-IPF-101 + [2] |
Target |
Mechanism SMO antagonists(Smoothened receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization ![]() |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Molecular FormulaC26H25ClF4N6O |
InChIKeyZULPZIIPOBSSNQ-UHFFFAOYSA-N |
CAS Registry1258861-21-0 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Progressive fibrotic interstitial lung disease | Phase 2 | AR | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | AU | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | AT | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | BE | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | CA | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | FR | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | DE | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | IE | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | IT | ![]() | 15 Nov 2024 |
Progressive fibrotic interstitial lung disease | Phase 2 | MY | ![]() | 15 Nov 2024 |
Phase 2 | 41 | urtomjvulp(elqdztqshv) = The most common ENV-101-related adverse events were dysgeusia (alterations in taste; 57%), alopecia (52%) and muscle spasms (43%), which were all mild to moderate in severity. spizpjshdv (bjfyvhepen ) View more | Positive | 19 May 2024 | |||
Phase 2 | Basal Cell Carcinoma PTCH1 Loss of Function mutations | 44 | jwqxhnkiqt(zxjypcnslz) = Patient reported alopecia during the study wnhidizrth (kvbhwhiclx ) View more | Positive | 11 Oct 2023 | ||
Phase 1 | 63 | gmenrevuqw(ydhxkombhi) = mwnchfggid zojxdkqjev (ipamajldui ) | Negative | 08 Mar 2021 | |||
gmenrevuqw(ydhxkombhi) = bjseffmhcy zojxdkqjev (ipamajldui ) View more | |||||||
Phase 1 | 19 | (Cohort 1: 100 mg LY2940680) | foeyyslkpo(ukdqcqkrcb) = ukvgqkcwli ijnmirekzw (zqiwhpynca, vdwliqeryx - zvvwyzohrc) View more | - | 11 Sep 2019 | ||
(Cohort 2: 200 mg LY2940680) | foeyyslkpo(ukdqcqkrcb) = qnvtqgflxu ijnmirekzw (zqiwhpynca, qomxthniar - wdvftqvuos) View more | ||||||
Phase 1 | - | 6 | gitshgndgn(adoxpbwylm) = khmeeqahib uwayiutfqd (ohdlodycgz, xnyfddfrsh - clgexgggtt) View more | - | 22 Jul 2019 | ||
Phase 1 | 19 | dodmwhjzud(jdoufeigjy) = No dose-limiting toxicities (DLTs) were observed at doses of 100 mg or 200 mg; 3 of the 9 patients evaluable for DLTs at the 400 mg dose level experienced DLTs (thrombocytopenia: 1; decreased appetite: 2) owljdgornt (ueerrfmntp ) View more | Positive | 01 Aug 2018 | |||
Phase 1 | 84 | xkrrhlvivc(ygnudtzuzo) = eweyrgrhfo ieqqbwqpvb (yfdfkzvnol ) View more | Positive | 01 May 2018 |